Top 5 Railroad Stocks To Buy For 2015

Let's face it, building pipeline to move oil and gas takes a long time, and several refiners and exploration and production companies just can't wait around for these pipes to get built. That is a large reason why HollyFrontier (NYSE: HFC  ) just announced that it and its midstream subsidiary Holly Energy Partners (NYSE: HEP  ) plan to add rail capacity of 70,000 barrels per day to its operations to move oil from Holly Energy's pipes in Southeast New Mexico to HollyFrontier's refining facilities in the region.�

HollyFrontier joins a growing list of refiners that are using rail to supply crude for its operations, and it looks as though this is a pretty advantageous relationship for both refiners and railroad companies. in this video, Fool.com contributor Tyler Crowe looks at some of the advantages of moving crude via rail has for both parties and if this trend will continue as more pipeline gets built.�

There are many different ways to play the energy sector, and The Motley Fool's analysts have uncovered an under-the-radar company that's dominating its industry. This company is a leading provider of equipment and components used in drilling and production operations, and poised to profit in a big way from it. To get the name and detailed analysis of this company that will prosper for years to come, check out our special free report: "The Only Energy Stock You'll Ever Need." Don't miss out on this limited-time offer and your opportunity to discover this under-the-radar company before the market does. Click here to access your report -- it's totally free.

Top 5 Railroad Stocks To Buy For 2015: AsiaInfo-Linkage Inc.(ASIA)

AsiaInfo-Linkage, Inc. provides telecommunications software solutions and information technology (IT) products and services to telecommunications carriers and other enterprises in the People?s Republic of China. The company offers business and operation support systems product suites, including OpenBilling, a billing solution for telecommunications operators; OpenCRM, a CRM solution suite for telecommunications operators; OpenBOSS, a carrier-class business operation support system solution; OpenBI, a carrier-class operating analysis and decision support system platform; OpenPRM, a system that calculates, manages, and reconciles payment for intercarrier network access. It also provides network management solutions comprising NetXpert, a data and Internet protocol network management solution; and OpenXpert, an integrated telecommunications network management system. In addition, the company offers service applications products, such as Mail Center, an online messaging softwa re; Spam Patrol software for real time anti-spam control; and Net Disk, a network hard disk product, which facilitates Internet-based file transfer, sharing, and management, as well as supports other functions, such as data processing of short message folders and synchronization of mobile devices. Its service applications products also include Internet Short Messaging Gateway, a business support platform for value-added short messaging services; and Device Management Platform that enables mobile operators to manage various mobile devices and perform remote mobile device management, such as remote diagnosis and parameter setup. In addition, it offers software enhancement and maintenance, system integration, and other value-added IT consulting and planning services. The company was formerly known as AsiaInfo Holdings, Inc. and changed its name to AsiaInfo-Linkage, Inc. in July 2010. AsiaInfo-Linkage, Inc. was founded in 1993 and is headquartered in Beijing, the People?s Republ ic of China.

Advisors' Opinion:

• [By Jonathan Burgos]

  ��arkets are entering a period of uncertainty,��said Yoji Takeda, Hong Kong-based head of Asian equities at RBC Investment (Asia) Ltd., which oversees $1.5 billion. ��here�� a policy vacuum in Japan and the government isn�� going to come up with new policies until parliament resumes sessions in September. While the possible tapering of U.S. stimulus has been more or less priced in, people tend to be a little bit cautious until it happens.��

Top 5 Railroad Stocks To Buy For 2015: Novartis AG (NVS)

Novartis AG, incorporated on February 29, 1996, provides healthcare solutions. The Company is a multinational group of companies specializing in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. Its portfolio includes medicines, eye care, cost-saving generic pharmaceuticals, preventive vaccines and diagnostic tools, over-the-counter and animal health products. The Company has five segments: Pharmaceuticals, which include patent-protected prescription medicines; Alcon, which include surgical, ophthalmic pharmaceutical and vision care products; Sandoz, which include generic pharmaceuticals; vaccines and diagnostics, which include human vaccines and blood-testing diagnostics, and consumer health, which include over-the-counter medicines (OTC) and Animal Health. On April 8, 2011, the Company acquired the remaining non-controlling interest in Alcon, Inc. In December 2013, Alliance Pharma plc announced that its wholly owned subsidiary, Alliance Pharmaceuticals Limited, acquired all the United Kingdom and Republic of Ireland (ROI) rights to Lypsyl from Novartis AG.

In April 2011, Novartis sells global rights to Elidel, a medicine to treat atopic dermatitis to Meda. In March 2011, Novartis completes acquisition of majority stake in Zhejiang Tianyuan vaccines company in China. In March 2011, the Company acquired Genoptix, Inc. In October 2011, Novartis discontinues development of AGO178 for depressive disorder. In December 2011, the Company discontinues development of PRT128 for acute coronary syndrome and chronic coronary heart disease, and SMC021 for osteoporosis and osteoarthritis. In April 2011, Alcon's portfolio of generic ophthalmic medicines sold through its Falcon business unit primarily in the United States.

Pharmaceuticals Division

The Company�� Pharmaceuticals Division researches, develops, manufactures, distributes and sells patented prescription medicines in the therapeutic areas, such as Oncol! ogy; Primary Care, consisting of Primary Care medicines and Established Medicines, and Specialty Care, consisting of Ophthalmology, Neuroscience, Integrated Hospital Care, and Critical Care medicines. The Pharmaceuticals Division is organized into global business franchises responsible for the commercialization of various products, as well as Novartis Oncology, a business unit responsible for the global development and commercialization of oncology products, and Novartis Molecular Diagnostics, a business responsible for the development and commercialization of diagnostic tests and services related to its pharmaceuticals portfolio and therapeutic areas.

The Company�� Oncology products include Afinitor/Votubia, Exjade, Sandostatin SC/Sandostatin LAR , Femara , Zometa, Tasigna and Gleevec/Glivec. Gleevec/Glivec, which is a signal transduction inhibitor approved to treat patients with certain forms of chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GIST). Tasigna is a signal transduction inhibitor of the tyrosine kinase activity of Bcr-Abl, KIT+ and the PDGF-receptor. Zometa is a treatment to reduce or delay skeletal-related events (SREs), including pathologic fracture, spinal cord compression, and/or requirement of radiation therapy or surgery to bone, in patients with bone metastases (cancer that has spread to the bones) from solid tumors and multiple myeloma. Femara is a once-daily oral aromatase inhibitor for the treatment of early stage or advanced breast cancer in postmenopausal women. Sandostatin SC/Sandostatin LAR is indicated for the treatment of patients with acromegaly, a chronic disease caused by over-secretion of pituitary growth hormone in adults. Sandostatin is also indicated for the treatment of patients with certain symptoms associated with carcinoid tumors and other types of gastrointestinal and pancreatic neuroendocrine tumors. Exjade is an oral iron chelator approved for the treatment of chronic iron overload due to blood transfusions in patients over ! two years! of age who have a range of underlying anemias. Patients with congenital and acquired chronic anemia, such as thalassemia, sickle cell disease and myelodysplastic syndromes, require transfusions, which puts them at risk of iron overload. Afinitor/Votubia is an oral inhibitor of the mTOR pathway.

The Company�� Primary Care products include Arcapta Neohaler/Onbrez Breezhaler, Diovan, Exforge, Tekturna/Rasilez, Galvus, Reclast/Aclasta, Voltaren/Cataflam, Ritalin, Ritalin LA, Focalin and Focalin XR. Its Specialty Care products include Lucentis, Gilenya, Exelon, Extavia and Comtan, and Stalevo. Its Integrated Hospital Care include Zortress/Certican, Ilaris, Neoral and Myfortic.The Company�� Critical Care products include Xolair and Tobi Podhaler. As of December 31, 2011, the products under development includes ACZ885, which is being investigated for the secondary prevention of cardiovascular events and for the treatment of Diabetes Mellitus; AEB071 (sotrastaurin) is a low molecular weight, selective inhibitor of protein kinase-C (PKC); AFQ056 (mavoglurant) is a metabotropic glutamate receptor 5 (mGluR5) antagonist in Phase II development for the treatment of Parkinson's disease levodopa-induced dyskinesia; AIN457 (secukinumab) is a human monoclonal antibody neutralizing interleukin-17A, a key pro-inflammatory cytokine expressed by TH17 cells and other types of white blood cells; BAF312 is an oral, second-generation sphingosine 1-phosphate receptor modulator in Phase II development for relapsing-remitting multiple sclerosis; DEB025 (alisporivir) is a cyclophilin inhibitor for the treatment of Hepatitis C virus infection (HCV); Gileny a line treatment for relapsing forms of MS; Exjade (deferasirox) is an oral iron chelator in development for use in patients with non-transfusion-dependent thalassemia (NTDT); INC424 (ruxolitinib) is an investigational Janus kinase (JAK) inhibitor, and Zortress/Certican (everolimus) is an mTOR inhibitor with immune/non-immune cell proliferation inhibition being d! eveloped ! for prevention of solid organ transplant rejection.

Alcon Division

The Company�� Alcon Division discovers, develops, manufactures, distributes and sells eye care products. Alcon is engaged in eye care with product offerings in Surgical, Ophthalmic Pharmaceuticals and Vision Care. In Surgical, Alcon develops, manufactures, distributes and sells ophthalmic surgical equipment, instruments, disposable products and intraocular lenses. In Pharmaceutical, Alcon discovers, develops, manufactures, distributes and sells medicines to treat chronic and acute diseases of the eye, as well as over-the-counter medicines for the eye. In Vision Care, Alcon develops, manufactures, distributes and sells contact lenses and lens care products.

Alcon's Surgical portfolio includes the Infiniti vision system for cataract procedures, the Constellation vision system for retinal operations, and the AcrySof family of intraocular lenses (IOLs), including the AcrySof IQ, AcrySof IQ ReSTOR, AcrySof IQ Toric and AcrySof IQ ReSTOR Toric IOLs. During the year ended December 31, 2011, its Alcon Division launched the LenSx femtosecond laser, a technology in cataract surgery, which increases the precision and reproductibility for corneal incisions, capsulorhexis and lens fragmentation steps of the procedure. In addition, Alcon provides advanced viscoelastics, surgical solutions, surgical packs and other disposable products for cataract and vitreoretinal surgery.

Alcon Division's Ophthalmic Pharmaceuticals business combines Alcon's range of pharmaceuticals with selected ophthalmic products (excluding Lucentis) previously marketed by the Novartis Pharmaceuticals Division. The products treat chronic and acute diseases of the eye including glaucoma and allergies, as well as anti-infective/anti-inflammatory and dry eye treatments. our Alcon Division's Ophthalmic Pharmaceuticals portfolio include Travatan Z solution and DuoTrav solution for the treatment of elevated intraocular pressure associ! ated with! glaucoma; Vigamox solution for bacterial conjunctivitis; Pataday solution for ocular itching associated with allergic conjunctivitis; and Nevanac suspension for eye inflammation following cataract surgery. Alcon launched a number of products during 2011, including Dailies Total 1 lenses, Opti-Free EverMoist Multi Purpose Disinfecting Solution, LenSx laser, AcrySof IQ ReSTOR Toric lens, AcrySof IQ Toric T6-T9 lens, Travatan BAK-free solution, DuoTrav BAK-free solution, Moxeza solution and Systane Balance eye drops.

Sandoz Division

The Company�� Sandoz Division is a global generic pharmaceuticals company that develops, manufactures, distributes and sells prescription medicines, as well as pharmaceutical and biotechnological active substances, which are not protected by valid and enforceable third-party patents. The Sandoz Division has activities in Retail Generics, Anti-Infectives, and Biopharmaceuticals and Oncology Injectables. In Retail Generics, Sandoz develops, manufactures and markets active ingredients and finished dosage forms of pharmaceuticals, as well as supplying active ingredients to third parties. In Anti-Infectives, Sandoz develops and manufactures active pharmaceutical ingredients and intermediates, mainly antibiotics, for internal use by retail generics and for sale to third-party customers. In Biopharmaceuticals, Sandoz develops, manufactures and markets protein- or other biotechnology-based products (biosimilars or follow-on biologics) and sells biotech manufacturing services to other companies.

In Oncology Injectables, Sandoz develops, manufactures and markets primarily cytotoxic products for the hospital market. During 2011, the Company launched generic docetaxel (Taxotere), higher-strength generic amlodipine-benazepril (Lotrel), generic meropenem (Merem) injection, and the formation of a women's health portfolio with generic Seasonale, Nordette, Yaz and Yasmin. The product launched in various European countries included generic docetaxel, ge! neric ana! strazole (Arimidex), and valsartan/covalsartan (an early entry generic version of Novartis Pharmaceuticals' Diovan/Co-Diovan).

Vaccines and Diagnostics Division

The Company�� Vaccines and Diagnostics Division researches, develops, manufactures, distributes and sells preventive vaccines and diagnostic tools. Novartis Vaccines is a global developer and manufacturer of human vaccines. Novartis Diagnostics is a blood testing and molecular diagnostics business dedicated to preventing the spread of infectious diseases through blood-screening tools that protect the world's blood supply. Novartis Vaccines' products include influenza, meningococcal, pediatric, adult and travel vaccines.

The Company�� influenza vaccines include Agrippal, Fluad, Fluvirin and Optaflu. Its Meningococcal Vaccines includes Menjugate and Menveo. Its travel vaccines include Encepur Children, Encepur Adults, Ixiaro and Rabipur/Rabavert. Its Pediatric Vaccines include Polioral and Quinvaxem.

Consumer Health

Consumer Health consists of two Divisions: OTC (over-the-counter medicines) and Animal Health. Each has its own research, development, manufacturing, distribution and selling capabilities. OTC offers readily available consumer medicine. Animal Health provides veterinary products for farm and companion animals.

OTC (over-the-counter medicines) offers products for the treatment and prevention of common medical conditions and ailments. OTC business focuses on a group of global brands in product categories that include treatments for cough/cold/respiratory (Triaminic, Otrivin, TheraFlu/NeoCitran), pain relief (Excedrin, Voltaren), digestive health (Benefiber, Prevacid24HR, Pantoloc Control), dermatology (Lamisil, Fenistil), and smoking cessation (Habitrol/Nicotinell).

Animal Health offers products and services focusing on both companion and farm animals (including cultivated fish). Key products for companion animals include Atopica (atopic dermatitis manageme! nt), Dera! maxx and Onsior (pain relief), Fortekor (heart failure in dogs, chronic renal insufficiency in cats), and Sentinel/Milbemax/Interceptor (intestinal parasite control and heartworm prevention), while farm animal products include the therapeutic anti-infective Denagard, an antimicrobial used to treat and control bacteria in swine, CLiK, an insect growth regulator used to control blowfly strike in sheep, cattle vaccines used to prevent respiratory and reproductive diseases in beef and dairy cattle, and Zolvix, a sheep drench representing the new sheep anthelmintic class. Aquaculture products include vaccines and treatments mainly used in salmon farming.

Advisors' Opinion:

• [By WALLSTCHEATSHEET]

  Novartis is a healthcare company that provides a number of healthcare products and services to consumers and companies worldwide. Speculation surrounding a merger between Novartis and Roche Holding Ltd. is unwarranted. The stock has been on a strong run, but is now pulling back. Over the last four quarters, earnings and revenues have been increasing, which has left investors pleased. Relative to its peers and sector, Novartis has been a poor year-to-date performer. Look for Novartis to OUTPERFORM.

• [By Vanina Egea]

  The first on the list is Pfizer Inc.�(PFE), in which Blackhill disclosed a $23.6 million stake with over 772,140 shares. Pfizer is a biopharmaceutical company which sells health care products worldwide. It operates in a highly competitive industry with Merck & Co. Inc. (MRK), Novartis AG (NVS) and Sanofi (SNY). It has reported fourth quarter EPS and revenues above the Zacks Consensus Estimate. It has a proven commitment to returning cash to investors, with a current dividend yield of 3% which is considered quite good to protect investors' purchasing power. The company returned about $15 billion to shareholders (dividends and share buybacks) in 2012.

• [By Keith Speights]

  Earlier this week, Questcor announced that it's buying rights to Synacthen from Novartis (NYSE: NVS  ) for $135 million plus potential milestone payments. Synacthen is a synthetic form of adrenocorticotropic hormone, or ACTH, and has been viewed as a potential threat to Questcor's Acthar gel. While Synacthen isn't yet available in the U.S., the drug sells elsewhere in the world for only a fraction of Acthar's cost.

Top Supermarket Companies To Buy For 2015: Swissquote Group Holding Ltd (SQN)

Swissquote Group Holding Ltd (Swissquote) is a provider of online financial and trading services in Switzerland. It operates an online bank that accepts deposits from its customers mainly in Swiss Francs, United States Dollars and Euros in current account form, as well as offers electronic dealing in shares, funds, options, warrants and bonds worldwide. Swissquote also provides stock brokerage services to self-directed investors and asset managers; custodian services against fees and foreign exchange; margin loans to customers against pledging of assets; fiduciary placements on behalf and at the risks of clients against commission fees and services to corporations for the management of their stock option programs, among others. Its financial portal swissquote.ch is an online platform providing the information that users need to conduct independent research on various investment vehicles. It is active domestically and abroad, including Dubai and Malta. Advisors' Opinion:

• [By Tom Stoukas]

  Swissquote Group Holding SA (SQN) surged 13 percent after agreeing to buy MIG Bank for an undisclosed price. Clariant AG lost 1.6 percent after UBS AG removed the maker of specialty chemicals from the list of its most preferred shares.

Top 5 Railroad Stocks To Buy For 2015: Mesabi Trust (MSB)

Mesabi Trust operates as a royalty trust in the United States. The company produces iron ore pellets. It holds interest in the Peter Mitchell mine located in the Mesabi Iron Range near Babbitt, Minnesota. The company holds various agreements with the Northshore Mining Company that mines iron ore, which is in the form of taconite, crushes it, separates the iron particles from the non-metallic, and forms the resulting concentrate into pellets that are shipped for use in steel-producing blast furnaces of customers of CCI, a mining company that produces iron pellets in North America. Mesabi Trust was founded in 1919 and is based in New York, New York.

Advisors' Opinion:

• [By Selena Maranjian]

  Patience, Grasshopper
  For starters, imagine that you invested in Mesabi Trust (NYSE: MSB  ) about a year ago and you're down some 20% on your investment. Your holding might be looking to you like an answer to the question, "What is investment panic, Alex?" But don't be so hasty. Ask yourself why you bought it. Mesabi Trust is a royalty trust that receives and then pays out to shareholders a portion of the proceeds from iron mined by a�Cliffs Natural Resources�subsidiary. Some might avoid it because royalty trusts often have expiration dates, but it's worth noting that Mesabi's is rather�far away. But slowdown in demand�for ore is a concern, one that has been�an issue for Cliffs, too.

Top 5 Railroad Stocks To Buy For 2015: Creston PLC (CRE)

Creston Plc is a United Kingdom-based company engaged in insight and communications services. The Company operates in three divisions: Communications division, which offers clients an integrated approach to their marketing and communication strategy, offering a range of services, which include advertising, brand strategy, channel marketing, customer relationship marketing, digital marketing, direct marketing, local marketing, social media marketing and public relations; Health division, which provides an integrated communications solution to the healthcare and pharmaceutical sector and offers services, which include advertising, advocacy, digital and direct marketing, public relations, issues and reputation management and medical education; Insight division, which performs a range of market research services on behalf of its clients, through both qualitative and quantitative means, using face-to-face, telephone and online data collection techniques. Advisors' Opinion:

• [By Investment Biker]

  Over the years, WAL has changed its loan origination strategy. Post crisis, WAL's i) loan growth has been driven by commercial real estate (CRE) and Commercial & Industrial loans (C&I), ii) Construction and development share of loans has reduced from 24% in 2005 to 7% in 1Q'2013 and iii) completely cessation of new loan origination in the residential mortgage segment.